A trial of datopotamab deruxtecan for breast cancer (TROPION-Breast01)

Overview

Cancer types:

Breast cancer, Secondary cancers

Status:

Results

Phase:

Phase 3

Details

Who the trial was for

This trial was for people with breast cancer that:

  • could not be removed with surgery or had spread to another part of the body

  • had a large number of hormone receptors ( or HR positive cancer)

  • had a small number of receptors for the protein HER2 ()

What the trial looked at

The trial compared standard chemotherapy with a called datopotamab deruxtecan.

What the results showed

The results showed that datopotamab deruxtecan can help stop breast cancer growing more than standard chemotherapy. This is for people whose cancer has spread or can't be removed with surgery.

Recruitment start: 18 October 2021

Recruitment end: 22 December 2022

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Peter Schmid

Supported by

AstraZeneca

Last reviewed: 24 Sept 2026

CRUK internal database number: 17902

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and Support

An icon of a hand shake.

Find a Clinical Trial

Search our clinical trials database for all cancer trials and studies recruiting in the UK.

An icon of two speech bubbles, indicating a conversation.

Cancer Chat forum

Connect with other people affected by cancer and share your experiences.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.

An icon of a navy envelope.

Get the information that's right for you

Whether you're living with cancer or supporting someone who is, sign up and receive weekly trusted information straight to your inbox.